|
1
|
Massry SG and Glassock RJ: Massry &
Glassock's textbook of nephrology. Lippincott Williams &
Wilkins; Philadelphia, PA; pp. 701–713. 2001
|
|
2
|
Ronco P and Debiec H: Pathogenesis of
membranous nephropathy: Recent advances and future challenges. Nat
Rev Nephrol. 8:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waldman M and Austin HA III: Treatment of
idiopathic membranous nephropathy. J Am Soc Nephrol. 23:1617–1630.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kidney Disease: Improving Global Outcomes
(KDIGO): KDIGO Clinical Practice Guideline for Glomerulonephritis.
Kidney Int Suppl. 2:139–274. 2012.
|
|
5
|
Perna A, Schieppati A, Zamora J, Giuliano
GA, Braun N and Remuzzi G: Immunosuppressive treatment for
idiopathic membranous nephropathy: A systematic review. Am J Kidney
Dis. 44:385–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schieppati A, Perna A, Zamora J, Giuliano
GA, Braun N and Remuzzi G: Immunosuppressive treatment for
idiopathic membranous nephropathy in adults with nephrotic
syndrome. Cochrane Database Syst Rev. 18:CD0042932004.
|
|
7
|
Scott LJ, McKeage K, Keam SJ and Plosker
GL: Tacrolimus: A further update of its use in the management of
organ transplantation. Drugs. 63:1247–1297. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramachandran R, Hn HK, Kumar V, Nada R,
Yadav AK, Goyal A, Kumar V, Rathi M, Jha V, Gupta KL, et al:
Tacrolimus combined with corticosteroids versus Modified Ponticelli
regimen in treatment of idiopathic membranous nephropathy:
Randomized control trial. Nephrology (Carlton). 21:139–146. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramachandran R, Kumar V, Nada R, Kohli HS,
Jha V and Gupta KL: Tacrolimus with corticosteroids is inferior to
modified Ponticelli regimen in the management of primary membranous
nephropathy: Results at 2 years of randomization. Nephrol Dial
Transplant. 31(Suppl 1): i772016. View Article : Google Scholar
|
|
10
|
Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang
W, Li X, Pan X and Chen N: Tacrolimus combined with corticosteroids
in idiopathic membranous nephropathy: A randomized, prospective,
controlled trial. Contrib Nephrol. 181:152–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Debiec H, Guigonis V, Mougenot B, Decobert
F, Haymann JP, Bensman A, Deschênes G and Ronco PM: Antenatal
membranous glomerulonephritis due to anti-neutral endopeptidase
antibodies. N Engl J Med. 346:2053–2060. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin W, Beck LH Jr, Zeng C, Chen Z, Li S,
Zuo K, Salant DJ and Liu Z: Anti-phospholipase A2 receptor antibody
in membranous nephropathy. J Am Soc Nephrol. 22:1137–1143. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prunotto M, Carnevali ML, Candiano G,
Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto
A, Santucci L, et al: Autoimmunity in membranous nephropathy
targets aldose reductase and SOD2. J Am Soc Nephrol. 21:507–519.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Schieppati A, Cai G, Chen X,
Zamora J, Giuliano GA, Braun N and Perna A: Immunosuppression for
membranous nephropathy: A systematic review and meta-analysis of 36
clinical trials. Clin J Am Soc Nephrol. 8:787–796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF,
Li XW, Chen JH and Wang HY; Chinese Nephropathy Membranous Study
Group: Tacrolimus combined with corticosteroids in treatment of
nephrotic idiopathic membranous nephropathy: A multicenter
randomized controlled trial. Am J Med Sci. 339:233–238. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi JC, Liu PG, Wang C, Zheng AD and Wan Z:
Tacrolimus protects vascular endothelial cells from injuries caused
by Ox-LDL by regulating endoplasmic reticulum stress. Eur Rev Med
Pharmacol Sci. 21:3966–3973. 2017.PubMed/NCBI
|
|
17
|
Santosh T, Liu H and Liu B: Effect of
tacrolimus in idiopathic membranous nephropathy: A meta-analysis.
Chin Med J (Engl). 127:2693–2699. 2014.PubMed/NCBI
|
|
18
|
Ballarin J, Poveda R, Ara J, Pérez L,
Calero F, Grinyó JM and Romero R: Treatment of idiopathic
membranous nephropathy with the combination of steroids, tacrolimus
and mycophenolate mofetil: Results of a pilot study. Nephrol Dial
Transplant. 22:3196–3201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arikan H, Koc M, Cakalagaoglu F, Eren Z,
Segal MS, Tuglular S, Ozener C and Akoglu E: Tacrolimus rescue
therapy in resistant or relapsing cases of primary
glomerulonephritis. J Nephrol. 21:713–721. 2008.PubMed/NCBI
|
|
20
|
Caro J, Gutiérrez-Solís E, Rojas-Rivera J,
Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos
MÁ, et al: Predictors of response and relapse in patients with
idiopathic membranous nephropathy treated with tacrolimus. Nephrol
Dial Transplant. 30:467–474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan H, Liu N, Sun GD, Jia Y, Luo P and
Miao LN: Effect of prolonged tacrolimus treatment in idiopathic
membranous nephropathy with nephrotic syndrome. Pharmacology.
91:259–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yağmurdur MC, Sevmis S, Emiroğlu R, Moray
G, Bilgin N and Haberal M: Tacrolimus conversion in kidney
transplant recipients: Analysis of 107 patients. Transplant Proc.
36:144–147. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He L, Peng Y, Liu H, Liu Y, Yuan S, Liu F,
Yang D, Liu H, Chen X, Shao J and Fu M: Treatment of idiopathic
membranous nephropathy with combination of low-dose tacrolimus and
corticosteroids. J Nephrol. 26:564–571. 2013. View Article : Google Scholar : PubMed/NCBI
|
